{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:17:21Z","timestamp":1787681841881,"version":"build-2784847793"},"reference-count":88,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA029826-01A1"],"award-info":[{"award-number":["R21 DA029826-01A1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013043","name":"Yale Center for Clinical Investigation, Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.biopsych.2012.06.012","type":"journal-article","created":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T15:57:20Z","timestamp":1342627040000},"page":"871-879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the \u03ba Opioid Agonist Salvinorin A in Humans"],"prefix":"10.1016","volume":"72","author":[{"given":"Mohini","family":"Ranganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Schnakenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D.","family":"Skosnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Andrew","family":"Sewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Cyril","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2012.06.012_bib1","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1124\/jpet.103.059394","article-title":"Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: Structural and functional considerations","volume":"308","author":"Chavkin","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2012.06.012_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drugalcdep.2006.04.001","article-title":"Pattern of use and subjective effects of Salvia divinorum among recreational users","volume":"85","author":"Gonzalez","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2012.06.012_bib3","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2012.06.012_bib4","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.addbeh.2011.06.004","article-title":"Correlates of Salvia divinorum use in a national sample: findings from the 2009 National Survey on Drug Use and Health","volume":"36","author":"Ford","year":"2011","journal-title":"Addict Behav"},{"key":"10.1016\/j.biopsych.2012.06.012_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.drugalcdep.2010.05.003","article-title":"Use patterns and self-reported effects of Salvia divinorum: An internet-based survey","volume":"111","author":"Baggott","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2012.06.012_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.drugalcdep.2009.11.010","article-title":"Salvia divinorum: Effects and use among YouTube users","volume":"108","author":"Lange","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2012.06.012_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/02791072.2010.10400701","article-title":"Influence of age on Salvia divinorum use: Results of an Internet survey","volume":"42","author":"Nyi","year":"2010","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.biopsych.2012.06.012_bib8","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/0269881110385596","article-title":"Salvia divinorum use and phenomenology: Results from an online survey","volume":"25","author":"Sumnall","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib9","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4088\/JCP.v69n0919c","article-title":"Toxic psychosis after intake of the hallucinogen salvinorin A","volume":"69","author":"Paulzen","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2012.06.012_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drugalcdep.2006.04.001","article-title":"Pattern of use and subjective effects of Salvia divinorum among recreational users","volume":"85","author":"Gonzalez","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2012.06.012_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/mi.6.5.7","article-title":"Salvinorin A: from natural product to human therapeutics","volume":"6","author":"Vortherms","year":"2006","journal-title":"Mol Interv"},{"key":"10.1016\/j.biopsych.2012.06.012_bib12","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/rcm.1970","article-title":"Quantification of the plant-derived hallucinogen Salvinorin A in conventional and non-conventional biological fluids by gas chromatography\/mass spectrometry after Salvia divinorum smoking","volume":"19","author":"Pichini","year":"2005","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.biopsych.2012.06.012_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.drugalcdep.2010.11.005","article-title":"Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum","volume":"115","author":"Johnson","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2012.06.012_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00213-010-2103-5","article-title":"Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: A placebo-controlled trial","volume":"214","author":"Mendelson","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0378-8741(94)90116-3","article-title":"Salvia divinorum and salvinorin A: New pharmacologic findings","volume":"43","author":"Siebert","year":"1994","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00213-011-2470-6","article-title":"Acute and post-acute behavioral and psychological effects of salvinorin A in humans","volume":"220","author":"Addy","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.psyneuen.2008.01.006","article-title":"Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys","volume":"33","author":"Pascoe","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.biopsych.2012.06.012_bib18","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1210\/endo.131.6.1332851","article-title":"Mu- and kappa-opiate receptor control of prolactin secretion in rats: Ontogeny and interaction with serotonin","volume":"131","author":"Blackford","year":"1992","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopsych.2012.06.012_bib19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.bjp.0700971","article-title":"The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man","volume":"120","author":"Ur","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0091-3057(94)00384-U","article-title":"Effects of highly selective kappa-opioid agonists on EEG power spectra and behavioural correlates in conscious rats","volume":"51","author":"Coltro Campi","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2012.06.012_bib21","first-page":"3724","article-title":"EEG complexity drug-induced changes in disorders of consciousness: A preliminary report","volume":"2011","author":"Valenza","year":"2011","journal-title":"Conf Proc IEEE Eng Med Biol Soc"},{"key":"10.1016\/j.biopsych.2012.06.012_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.npp.1300596","article-title":"Mu-opioid self-administration vs passive administration in heroin abusers produces differential EEG activation","volume":"30","author":"Greenwald","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2012.06.012_bib23","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1162\/jocn.2009.21355","article-title":"Cannabinoid modulations of resting state EEG theta power and working memory are correlated in humans","volume":"22","author":"Bocker","year":"2010","journal-title":"J Cogn Neurosci"},{"key":"10.1016\/j.biopsych.2012.06.012_bib24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/schbul\/sbn021","article-title":"Genetic and disorder-specific aspects of resting state EEG abnormalities in schizophrenia","volume":"35","author":"Venables","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2012.06.012_bib25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0006-3223(00)00907-0","article-title":"Clinical and biological concomitants of resting state EEG power abnormalities in schizophrenia","volume":"48","author":"Sponheim","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.06.012_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2009.06.044","article-title":"Salvinorin A and derivatives: Protection from metabolism does not prolong short-term, whole-brain residence","volume":"57","author":"Hooker","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2012.06.012_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/00952990.2011.600397","article-title":"Use of Salvia divinorum in a Nationally Representative Sample","volume":"38","author":"Perron","year":"2011","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.biopsych.2012.06.012_bib28","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis","volume":"29","author":"D'Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2012.06.012_bib29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2012.06.012_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2008.02.020","article-title":"The psychotomimetic states inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis","volume":"103","author":"Mason","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2012.06.012_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J Trauma Stress"},{"key":"10.1016\/j.biopsych.2012.06.012_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","article-title":"Dose-response study of N,N-dimethyltryptamine in humans","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2012.06.012_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","article-title":"Human psychopharmacology of N,N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1996","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2012.06.012_bib34","series-title":"Administration and Scoring Manual for the Wechsler Adult Intelligence Scale","author":"Wechsler","year":"1997"},{"key":"10.1016\/j.biopsych.2012.06.012_bib35","series-title":"Nonparametric Analysis of Longitudinal Data in Factorial Experiments","author":"Brunner","year":"2002"},{"key":"10.1016\/j.biopsych.2012.06.012_bib36","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archpsyc.62.9.985","article-title":"Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function","volume":"62","author":"Krystal","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2012.06.012_bib37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1124\/jpet.106.112417","article-title":"Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans","volume":"320","author":"Butelman","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2012.06.012_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0014-2999(99)00640-8","article-title":"Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys","volume":"383","author":"Butelman","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0014-2999(01)01121-9","article-title":"kappa-Opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists","volume":"423","author":"Butelman","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib40","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0306-4522(98)00251-6","article-title":"Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: A 33P in situ hybridization study","volume":"88","author":"Peckys","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2012.06.012_bib41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0306-4522(99)00344-9","article-title":"Mu and kappa1 opioid-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in cynomolgus monkey brain","volume":"94","author":"Sim-Selley","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2012.06.012_bib42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.105.092304","article-title":"Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats","volume":"316","author":"Carlezon","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2012.06.012_bib43","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00213-004-2087-0","article-title":"Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors","volume":"179","author":"Zhang","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.neuropharm.2009.07.023","article-title":"Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals","volume":"57","author":"Grilli","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2012.06.012_bib45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000118317","article-title":"Pentazocine and flupirtine effects on spontaneous and evoked EEG activity","volume":"16","author":"Bromm","year":"1986","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.biopsych.2012.06.012_bib46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00005053-195409000-00001","article-title":"Clinical and electroencephalographic studies on the effects of mescaline, N-allylnormorphine and morphine in man; a pharmacologic analysis of the functions of the spontaneous electrical activity of the cerebral cortex","volume":"120","author":"Wikler","year":"1954","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.biopsych.2012.06.012_bib47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1365-2125.2002.01609.x","article-title":"Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers","volume":"53","author":"Riba","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib48","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.clinph.2006.05.011","article-title":"Increase in high frequency EEG activity explains the poor performance of EEG spectral entropy monitor during S-ketamine anesthesia","volume":"117","author":"Maksimow","year":"2006","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib49","first-page":"193","article-title":"Kappa agonist-induced reduction in dopamine release: site of action and tolerance","volume":"78","author":"Donzanti","year":"1992","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib50","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.89.6.2046","article-title":"Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway","volume":"89","author":"Spanagel","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2012.06.012_bib51","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0022-3565(25)24578-5","article-title":"Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats","volume":"244","author":"Di Chiara","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2012.06.012_bib52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00213-003-1716-3","article-title":"Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL\/6J mice","volume":"173","author":"Zhang","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0006-8993(87)91571-X","article-title":"Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists","volume":"436","author":"Shippenberg","year":"1987","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2012.06.012_bib54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00444692","article-title":"Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated","volume":"98","author":"Bals-Kubik","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib55","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0021-5198(19)39723-9","article-title":"The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference","volume":"58","author":"Suzuki","year":"1992","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-002-1028-z","article-title":"Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats","volume":"161","author":"Mori","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib57","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/BF02245810","article-title":"The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity","volume":"120","author":"Crawford","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0006-8993(95)00306-B","article-title":"Kappa opioid inhibition of morphine and cocaine self-administration in rats","volume":"681","author":"Glick","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2012.06.012_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-2999(98)00548-2","article-title":"Effects of cyclazocine on cocaine self-administration in rats","volume":"357","author":"Glick","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0014-2999(96)00961-2","article-title":"Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice","volume":"321","author":"Kuzmin","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s002130051016","article-title":"U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking","volume":"144","author":"Schenk","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0006-8993(93)90228-F","article-title":"The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat","volume":"616","author":"Heidbreder","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2012.06.012_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s002130000424","article-title":"Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine","volume":"150","author":"Vanderschuren","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib64","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00008877-200107000-00002","article-title":"Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity","volume":"12","author":"Collins","year":"2001","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s002130000476","article-title":"Reinstatement of extinguished drug-taking behavior in rats: Effect of the kappa-opioid receptor agonist, U69593","volume":"151","author":"Schenk","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00213-010-1812-0","article-title":"Regulation of cocaine-reinstated drug-seeking behavior by kappa-opioid receptors in the ventral tegmental area of rats","volume":"210","author":"Sun","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib67","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pbb.2009.09.002","article-title":"Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats","volume":"94","author":"Morani","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2012.06.012_bib68","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-3565(25)12305-7","article-title":"kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine","volume":"276","author":"Shippenberg","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2012.06.012_bib69","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/FBP.0b013e3283512c1e","article-title":"A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats","volume":"23","author":"Morani","year":"2012","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib70","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pbb.2009.09.002","article-title":"Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats","volume":"94","author":"Morani","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2012.06.012_bib71","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00213-004-2087-0","article-title":"Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors","volume":"179","author":"Zhang","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib72","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.biopsych.2007.07.020","article-title":"Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward","volume":"63","author":"Braida","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.06.012_bib73","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00213-003-1680-y","article-title":"Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats","volume":"172","author":"Todtenkopf","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib74","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0031-6865(99)00044-8","article-title":"Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse","volume":"74","author":"Neumeyer","year":"2000","journal-title":"Pharm Acta Helv"},{"key":"10.1016\/j.biopsych.2012.06.012_bib75","doi-asserted-by":"crossref","first-page":"E592","DOI":"10.1208\/aapsj070361","article-title":"Kappa opioids as potential treatments for stimulant dependence","volume":"7","author":"Prisinzano","year":"2005","journal-title":"AAPS J"},{"key":"10.1016\/j.biopsych.2012.06.012_bib76","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.biopsych.2008.05.029","article-title":"The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward","volume":"64","author":"Tomasiewicz","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2012.06.012_bib77","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1749-6632.2000.tb06678.x","article-title":"Interactions between kappa opioid agonists and cocaine","volume":"909","author":"Mello","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.biopsych.2012.06.012_bib78","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0740-5472(99)00074-4","article-title":"An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence","volume":"18","author":"Rothman","year":"2000","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2012.06.012_bib79","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats","volume":"305","author":"Mague","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2012.06.012_bib80","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/BF00432213","article-title":"Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning","volume":"86","author":"Mucha","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib81","first-page":"563","article-title":"Differential effects of mu and kappa opioid systems on motivational processes","volume":"75","author":"Shippenberg","year":"1986","journal-title":"NIDA Res Monogr"},{"key":"10.1016\/j.biopsych.2012.06.012_bib82","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s002130100788","article-title":"Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans","volume":"157","author":"Walsh","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2012.06.012_bib83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-3565(24)29312-5","article-title":"Enadoline and butorphanol: Evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans","volume":"299","author":"Walsh","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2012.06.012_bib84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1527-3458.2003.tb00248.x","article-title":"A review of the properties of spiradoline: A potent and selective kappa-opioid receptor agonist","volume":"9","author":"Wadenberg","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.biopsych.2012.06.012_bib85","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jemermed.2009.05.019","article-title":"Salvia divinorum: Exposures reported to a statewide poison control system over 10 years","volume":"40","author":"Vohra","year":"2011","journal-title":"J Emerg Med"},{"key":"10.1016\/j.biopsych.2012.06.012_bib86","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1176\/appi.ajp.2009.08121759","article-title":"Persistent psychosis associated with salvia divinorum use","volume":"166","author":"Przekop","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2012.06.012_bib87","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1017\/S1461145704004110","article-title":"Do we still believe in the dopamine hypothesis?","volume":"7","author":"Abi-Dargham","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2012.06.012_bib88","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.biopsych.2005.02.030","article-title":"Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats","volume":"57","author":"Bortolato","year":"2005","journal-title":"Biol Psychiatry"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322312005458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322312005458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:57:14Z","timestamp":1757775434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322312005458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0006322312005458"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2012.06.012","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the \u03ba Opioid Agonist Salvinorin A in Humans","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2012.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}